| Hans-Günter Meyer-Thompson | Monatliche Neuheiten
Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
Johnson B, Monwell B, Capusan AJ.
Harm Reduct J. 2024 Mar 25;21(1):68. doi: 10.1186/s12954-024-00984-1. PMID: 38528531; PMCID: PMC10964574.
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-024-00984-1